Page 3 - Eric Endicott News Today

Investegate announcements from Prothena Corporation plc, Prothena to Participate in Stifel 2022 Virtual CNS Days

DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein

Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022 - read this article along with other careers information, tips and advice on BioSpace

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Oral presentation on preclinical data demonstrates Prothena's dual Aß/tau vaccine, for the potential treatment and prevention of Alzheimer's, generated anti-Aß and anti-tau antibodies to enable phagocytosis

Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full year 2021; quarter-end

Investegate announcements from Prothena Corporation plc, Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights

Investegate announcements from Prothena Corporation plc, Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022

- Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO, CA, May 5, 2021 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021. NUPLAZID delivered strong year-over-year performance in the first quarter of 2021. Looking ahead, we see positive signs in the Parkinsons disease psychosis market supporting revenue growth for the remainder of the year as we anticipate continued improvements in th...